Investors sold shares of Celgene Corp. (NASDAQ:CELG) on strength during trading hours on Friday. $102.76 million flowed into the stock on the tick-up and $176.19 million flowed out of the stock on the tick-down, for a money net flow of $73.43 million out of the stock. Of all companies tracked, Celgene Corp. had the 0th highest net out-flow for the day. Celgene Corp. traded up $0.93 for the day and closed at $112.19

Several brokerages have recently issued reports on CELG. Piper Jaffray Cos. set a $145.00 price target on shares of Celgene Corp. and gave the stock a “buy” rating in a research report on Thursday. Robert W. Baird reissued a “buy” rating and set a $162.00 price target on shares of Celgene Corp. in a research report on Tuesday, April 26th. Bank of America Corp. reissued a “buy” rating and set a $125.00 price target on shares of Celgene Corp. in a research report on Monday, April 25th. Vetr cut shares of Celgene Corp. from a “strong-buy” rating to a “buy” rating and set a $120.74 price target on the stock. in a research report on Thursday, June 2nd. Finally, Cowen and Company reissued a “buy” rating and set a $150.00 price target on shares of Celgene Corp. in a research report on Thursday. One analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-two have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $136.93.

The company’s 50 day moving average price is $102.41 and its 200-day moving average price is $103.04. The firm has a market capitalization of $87.69 billion and a P/E ratio of 47.42.

Celgene Corp. (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.39 by $0.05. During the same quarter last year, the firm posted $1.23 earnings per share. The firm earned $2.74 billion during the quarter, compared to the consensus estimate of $2.70 billion. Celgene Corp.’s revenue was up 20.9% compared to the same quarter last year. On average, analysts expect that Celgene Corp. will post $5.76 EPS for the current year.

In other news, insider Robert J. Hugin sold 75,000 shares of the business’s stock in a transaction that occurred on Monday, June 20th. The stock was sold at an average price of $100.16, for a total value of $7,512,000.00. Following the completion of the sale, the insider now directly owns 1,122,201 shares in the company, valued at approximately $112,399,652.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Several large investors have recently modified their holdings of CELG. Private Advisor Group LLC increased its stake in shares of Celgene Corp. by 32.3% in the fourth quarter. Private Advisor Group LLC now owns 70,366 shares of the biopharmaceutical company’s stock worth $8,427,000 after buying an additional 17,181 shares during the period. Mizuho Trust & Banking Co. Ltd. increased its stake in shares of Celgene Corp. by 1.5% in the fourth quarter. Mizuho Trust & Banking Co. Ltd. now owns 1,194,608 shares of the biopharmaceutical company’s stock worth $144,165,000 after buying an additional 17,117 shares during the period. Apriem Advisors increased its stake in shares of Celgene Corp. by 3.6% in the fourth quarter. Apriem Advisors now owns 22,605 shares of the biopharmaceutical company’s stock worth $2,707,000 after buying an additional 785 shares during the period. Quantitative Investment Management LLC purchased a new stake in shares of Celgene Corp. during the fourth quarter worth $5,389,000. Finally, Garcia Hamilton & Associates LP DE increased its stake in shares of Celgene Corp. by 1.2% in the fourth quarter. Garcia Hamilton & Associates LP DE now owns 29,170 shares of the biopharmaceutical company’s stock worth $3,493,000 after buying an additional 346 shares during the period.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.